Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
Angela Rocchi,1 Isabelle Chabot,2 Judith Glennie3 1Athena Research Inc., Burlington, ON, 2EvAccess Inc., Vaudreuil-Dorion, QC, 3JL Glennie Consulting Inc., Aurora, ON, Canada Background: In 2007, Canada chose to develop a separate and distinct path for oncology drug health technology assessment (HTA...
Saved in:
Main Authors: | Rocchi A (Author), Chabot I (Author), Glennie J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncology drug health technology assessment recommendations: Canadian versus UK experiences
by: Chabot I, et al.
Published: (2014) -
A Pan-Canadian Narrative Review on the Protocols for COVID-19 and Canadian Emergency Departments
by: Sebastian Diebel, et al.
Published: (2021) -
The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health
by: Chakrapani Balijepalli, et al.
Published: (2024) -
Cultural adaptation of the Pan-Canadian Oncology Symptom triage and remote support practice guide for cancer-related fatigue in China: Integration of traditional Chinese medicine nursing evidence
by: Meiqi Meng, et al.
Published: (2023) -
Training of advanced practice nurses in oncology for the best care: a systematic review
by: Franciane Schneider, et al.
Published: (2021)